Evidence map›Paper›PMID 36432734›Full record

ReviewPharmaceutics2022

Gut Dysbiosis and Diabetic Foot Ulcer: Role of Probiotics.

Ankit Awasthi, Leander Corrie, Sukriti Vishwas, Monica Gulati, Bimlesh Kumar, Dinesh Kumar Chellappan, Gaurav Gupta, Rajaraman D Eri, Kamal Dua, Sachin Kumar Singh

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Ankit AwasthiSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, India.
Leander CorrieSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, India.ORCID 0000-0002-1626-3513
Sukriti VishwasSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, India.
Monica GulatiSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, India.
Bimlesh KumarSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, India.
Dinesh Kumar ChellappanDepartment of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur 57000, Malaysia.ORCID 0000-0001-5567-6663
Gaurav GuptaSchool of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jaipur 302017, India.
Rajaraman D EriSchool of Health Sciences, The University of Tasmania, Launceston, TAS 7248, Australia.ORCID 0000-0003-1688-8043
Kamal DuaFaculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia.ORCID 0000-0002-7507-1159
Sachin Kumar SinghSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, India.ORCID 0000-0003-3823-6572
Lovely Professional University · INIMU University · MYUniversity of Tasmania · AUUniversity of Technology Sydney · AUUttaranchal University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic foot ulcer (DFU) is a multifactorial disease and one of the complications of diabetes. The global burden of DFU in the health sector is increasing at a tremendous rate due to its cost management related to hospitalization, medical costs and foot amputation. Hence, to manage DFU/DWs, various attempts have been made, including treating wounds systematically/topically using synthetic drugs, herbal drugs, or tissue engineering based surgical dressings. However, less attention has been paid to the intrinsic factors that are also the leading cause of diabetes mellitus (DM) and its complications. One such factor is gut dysbiosis, which is one of the major causes of enhancing the counts of Gram-negative bacteria. These bacteria produce lipopolysaccharides, which are a major contributing factor toward insulin resistance and inflammation due to the generation of oxidative stress and immunopathy. These all lead to DM and DFU. Probiotics are the commercial form of beneficial gut microbes that are taken as nutraceuticals by people of all ages to improve gut immunity and prevent gut dysbiosis. However, the role of probiotics has been less explored in the management of DFU. Hence, the therapeutic potential of probiotics in managing DFU is fully described in the current review. This report covers the linkage between gut dysbiosis and DFU, sources of probiotics, the mechanisms of probiotics in DW healing, and the impact of probiotic supplementation in treating DFU. In addition, techniques for the stabilization of probiotics, market status, and patents related to probiotics have been also covered. The relevant data were gathered from PubMed, Scopus, Taylor and Francis, Science Direct, and Google Scholar. Our systematic review discusses the utilization of probiotic supplementation as a nutraceutical for the management of DFU.

Indexed as

diabetic foot ulcermarket status of probioticspatents on probioticspathogenesissources of probioticstherapeutic potential of probiotics on DFU

Identifiers

PMID36432734
PMCPMC9699533
OpenAlexW4309543003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.